Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands
Open Access
- 13 August 2010
- journal article
- Published by Springer Nature in BMC Health Services Research
- Vol. 10 (1) , 237
Abstract
Herpes zoster (HZ) is a painful disease affecting a considerable part of the elderly. Programmatic HZ vaccination of elderly people may considerably reduce HZ morbidity and its related costs, but the extent of these effects is unknown. In this article, the potential effects and cost-effectiveness of programmatic HZ vaccination of elderly in the Netherlands have been assessed according to a framework that was developed to support evidence-based decision making regarding inclusion of new vaccines in the Dutch National Immunization Program.Keywords
This publication has 33 references indexed in Scilit:
- Cost Effectiveness of Herpes Zoster Vaccine in CanadaPharmacoEconomics, 2009
- Increased Risk of Stroke After a Herpes Zoster AttackStroke, 2009
- Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: Uptake of the first new vaccine to target seniorsVaccine, 2009
- Estimating the cost-effectiveness of vaccination against herpes zoster in England and WalesVaccine, 2009
- The Epidemiological, Clinical, and Pathological Rationale for the Herpes Zoster VaccineThe Journal of Infectious Diseases, 2008
- Development of Varicella VaccineThe Journal of Infectious Diseases, 2008
- Prevention of herpes zoster and its painful and debilitating complicationsInternational Journal of Infectious Diseases, 2007
- Cost-Effectiveness of a Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older AdultsClinical Infectious Diseases, 2007
- The burden of Herpes Zoster: A prospective population based studyVaccine, 2006
- A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older AdultsNew England Journal of Medicine, 2005